GILD News 70.00 Gilead Sciences (GILD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 70.00 $GILD

Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 5:30PM CDT
Investors focusing on Johnson and Johnson 's 3.5% top-line revenue growth in the first quarter are likely walking away unimpressed. However, tepid results in the company's medical device and consumer goods business mask much stronger growth in...

Final Glance: Biotechnology companies
AP - Thu Apr 17, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:

Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...

Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 1:30PM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...

If This Biotech Drops Much Further I'm Going to Buy It!
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 17, 12:05PM CDT
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a...

Early Glance: Biotechnology companies
AP - Thu Apr 17, 10:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:


UnitedHealth's 1Q profit tumbles 8 percent
By TOM MURPHY - AP - Thu Apr 17, 10:18AM CDT
UnitedHealth Group's first-quarter net income slid 8 percent as funding cuts to a key product and costs imposed by the health care overhaul dented the health insurer's performance.

Managers See Buys in Choppy Markets, Including Gilead, LinkedIn
at The Street - Thu Apr 17, 8:41AM CDT
Fund managers point to rich opportunity in choppy markets, even for those bearish on market direction.

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
No drug has hit the market running like Gilead Sciences '  freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the...

Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Young Scientists From Around the State Will Compete for Top Honors at the 63rd California State Science Fair
PR Newswire - Wed Apr 16, 5:31PM CDT
Over 1,000 of the state's top middle and high school students will convene for the final round of competition in the 63rd annual California State Science Fair, April 28-29, 2014 at the California Science Center in Exposition Park. Winners will take home a combined total of more than $50,000 in cash prizes. The Fair's presenting sponsor is Northrop Grumman Corporation with additional support from Chevron Corporation, Southern California Gas Company, THE MUSES of the California Science Center Foundation, The Ralph M. Parsons Foundation and Gilead Sciences, Inc.

Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences '  highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has overreacted to...

3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 16, 4:03PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...

Watch for Gilead Sciences to Potentially Pullback After Gaining 1.63% Yesterday
Comtex SmarTrend(R) - Wed Apr 16, 3:48PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $68.34 to a high of $69.89. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $69.14 on volume of 17.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Gilead Sciences Rises 1.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 16, 3:48PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $68.34 to a high of $69.89. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $69.14 on volume of 17.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Johnson and Johnson Earnings Surprises With Blockbuster Potential
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Apr 16, 1:52PM CDT
Editor's Note: In the video below, Olysio's sales for the quarter are identified as $365 million. Olysio's actual sales were $354 million. The Fool regrets the error. Johnson and Johnson reported quarterly earnings on Tuesday, and one...

The S&P 500's 3 Biggest Biotech Losers of 2014
Keith Speights, The Motley Fool - Motley Fool - Wed Apr 16, 1:30PM CDT
What goes up must come down. The law of gravity applies to physics -- and the stock market. This has been readily apparent in 2014 with biotech stocks. After taking the world by storm over the previous two years, many stocks in the sector instead...

Midday Glance: Biotechnology companies
AP - Wed Apr 16, 12:30PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:

Gilead Sciences Has Returned 12.6% Since SmarTrend Recommendation (GILD)
Comtex SmarTrend(R) - Wed Apr 16, 9:41AM CDT
SmarTrend identified a Downtrend for Gilead Sciences (NASDAQ:GILD) on March 13th, 2014 at $79.02. In approximately 1 month, Gilead Sciences has returned 12.56% as of today's recent price of $69.09.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 143

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 31

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 92

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 110

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 168

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 15

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 91

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 195

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading

Top 5 Most Recently Viewed Articles

New Leadership at KeyCorp: A Strategic Move for Risk Management

Updated Category News Views 304

KeyCorp Welcomes Mohit Ramani as Chief Risk Officer KeyCorp (NYSE: KEY), a prominent figure in the bank-based financial services industry, has made an important decision by announcing the appointment of Mohit (Mo) Ramani as its new Chief Risk Officer. This notable addition to the executive leadership team is seen as a strategic step towards enhancing the company's risk...

Continue Reading
Quaternary Ammonium Salts Market Expanding: Insights Ahead

Updated Category News Views 152

Exploring the Growth of the Quaternary Ammonium Salts Market The global quaternary ammonium salts market is on a remarkable growth trajectory, anticipated to reach a valuation of US$ 1,088.0 Million by the year 2034. With a robust CAGR of 5.9% from 2024 to 2034, this market is driven by increasing consumer awareness regarding hygiene and safety. Factors Driving Market...

Continue Reading
Generac's Upcoming Earnings: Key Details and Expectations

Updated Category News Views 147

Generac Prepares for Earnings Release and Conference Call Generac Holdings Inc. (NYSE: GNRC), known as a prominent leader in energy technology solutions, is gearing up for an important announcement. The company plans to unveil its fourth quarter and full-year 2024 financial results just before the market opens. The anticipated date for this release is set for an upcoming...

Continue Reading
AAVantgarde Ready for Key Presentations at EURetina 2025

Updated Category News Views 207

Significant Presentation at EURetina 2025 AAVantgarde Bio, a leading clinical-stage biotechnology company, is poised to present updated outcomes from its LUCE-1 clinical trial at the prestigious 25th European Society of Retina Specialists (EURETINA) Annual Congress in Paris. This event, scheduled from September 4-7, 2025, offers a vital platform for advancing discussions...

Continue Reading
Investing in WisdomTree Funds: Insights on Value and Performance

Updated Category News Views 246

Understanding the Value of WisdomTree Funds WisdomTree is known for its innovative approach to exchange-traded funds (ETFs). As investors seek ways to maximize their asset portfolios, understanding the net asset values (NAVs) of these funds becomes essential. In this article, we delve into various funds offered by WisdomTree, highlighting their date of valuation and key...

Continue Reading